Aardvark Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AARD and other ETFs, options, and stocks.

About AARD

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel, small-molecule therapeutics for the treatment of metabolic diseases. 

CEO
Tien Li Lee
CEOTien Li Lee
Employees
22
Employees22
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
2017
Founded2017
Employees
22
Employees22

AARD Key Statistics

Market cap
350.82M
Market cap350.82M
Price-Earnings ratio
-6.42
Price-Earnings ratio-6.42
Dividend yield
Dividend yield
Average volume
282.55K
Average volume282.55K
High today
$15.97
High today$15.97
Low today
$14.32
Low today$14.32
Open price
$15.97
Open price$15.97
Volume
267.18K
Volume267.18K
52 Week high
$19.58
52 Week high$19.58
52 Week low
$4.88
52 Week low$4.88

Stock Snapshot

As of today, Aardvark Therapeutics(AARD) shares are valued at $14.38. The company's market cap stands at 350.82M, with a P/E ratio of -6.42.

As of 2025-12-13, Aardvark Therapeutics(AARD) stock has fluctuated between $14.32 and $15.97. The current price stands at $14.38, placing the stock +0.4% above today's low and -10.0% off the high.

Aardvark Therapeutics(AARD) shares are trading with a volume of 267.18K, against a daily average of 282.55K.

During the past year, Aardvark Therapeutics(AARD) stock moved between $4.88 at its lowest and $19.58 at its peak.

During the past year, Aardvark Therapeutics(AARD) stock moved between $4.88 at its lowest and $19.58 at its peak.

AARD News

TipRanks 2d
Aardvark Therapeutics initiated with an Outperform at William Blair

William Blair initiated coverage of Aardvark Therapeutics (AARD) with an Outperform rating. The firm says Aardvark is advancing ARD-101, an oral therapy that ta...

TipRanks 3d
Aardvark Therapeutics doses first patient in HERO trial

Aardvark Therapeutics (AARD) announced that the first patient has been dosed in Australia in its Phase 3 HERO pivotal clinical trial assessing ARD-101 for the t...

Analyst ratings

100%

of 9 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own AARD. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.